by Weight loss medication can cause serious eye diseases that lead to visual loss in some people.
A study published in JamaRated data from almost 1.5 million people and found that there was an increased risk of optic nerve disorders in people with diabetes that took medication such as Semaglutid or Tirzepatide.
Research specifically characterizes a rare but devastating disease, which is referred to as a non-Arteritic anterior ischemic optics neuropathy or naion, whereby blood flow to the optic nerve is suddenly reduced or blocked, which leads to an “eye stroke”. The patients only notice it when they have lost eyesight in one eye, researchers write down The conversation.
There is no treatment for the disease.
In an earlier study, it was found that there was one of 10,000 chances that a patient Naion developed as a side effect of Semaglutide medication. However, the latest examinations showed that 35 of the 159,000 people with type -2 -diabetes Semaglutide or Tirepatid – developed about 1 to 2,500 – Naion.
“During the two -year follow -up examination, there were 35 patients with Naion in the Semaglutid or Tirzatide group,” said the researchers. “There were 93 patients with other optic nerve disorders.”
File. One patient receives laser treatment for diabetic retinopathy (AFP via Getty)
Another large study with 185,000 people published in the same magazine links weight loss medication that is known as GLP-1 RAS with an increased risk of diabetic retinopathy, which relates to blood vessels in the retina.
However, the participants in GLP-1 drugs in both studies saw fewer visual complications from diabetic retinopathy and required less invasive eye treatments than those that took other diabetes medication, as the researchers found.
Although researchers say that the general risk of developing such conditions by taking the drugs is low, they demand more precaution.
They also call for other long -term studies to understand how weight loss drugs can lead to eye complications.
“The cost of GLP-1 RAS must be weighed against the potential of these active ingredients in order to reduce the costs associated with the treatment of diabetes and its complications,” said the researchers.
The latest studies suggest that all diabetes patients with weight loss medication should be examined regularly regardless of the existing diabetic retinopathy and should be monitored for possible complications.
